Latest news with #weightloss
Daily Mail
4 hours ago
- Entertainment
- Daily Mail
Oprah Winfrey, 71, shows off her Ozempic weight loss in fitted gymwear as she enjoys a workout with Gayle King, 40, and Orlando Bloom, 48, in Venice ahead of Lauren Sanchez and Jeff Bezos' wedding
Oprah Winfrey showed off her slimmed-down figure as she enjoyed a pre-wedding workout with buddies Gayle King and Orlando Bloom in Venice on Friday morning. Ahead of Lauren Sanchez and Jeff Bezos ' ceremony that evening, the guests managed to squeeze in a jog around the cobbled streets. TV personality Oprah, 71, looked incredible as she displayed her weight loss in a fitted blue T-shirt and ribbed leggings. The talk show host - who once topped the scales at 237lbs in 1992 - finally reached her 160lb goal weight in 2023 after undergoing double-knee replacement surgery in 2021. After vehemently denying she had ever taken weight loss drugs, she finally admitted to taking them in a shock interview. Oprah lead the pack of celebrities flaunting much smaller physiques, alongside her best friend Gayle, 70, who has also dropped the pounds. The pair may have been on holiday but they were determined not to let their fitness levels drop She also dressed casually in a blue vest, teamed with a pair of fitted shorts. The duo bumped into Orlando, 48, on their workout, who chatted with the pair before continuing with his run. Earlier in the day the group had enjoyed breakfast at the Gritti Hotel amid the wedding celebrations, which are expected to continue until Sunday. A-list stars have flocked to the romantic city to attend the lavish wedding reveling in the opportunity to parade their slimmer bodies amid the Ozempic trend sweeping Hollywood. Leonardo DiCaprio, 50, looked considerably thinner as he arrived for the celebrations, although his method for recently transforming from tubby to trim remains a mystery. Kim Kardashian, 44, and her sisters also showcased their impossibly small waistlines. Her sister Khloe, 41, also showed off her gym-honed figure into a simple black summer dress as she went shopping with her leopard print clad mother Kris Jenner. But the bride-to-be was not to be outdone - with Sanchez, 55, wearing the most eye-popping corset of all to her pre-wedding party at the Madonna dell Orto cloisters on Thursday night. The talk show host - who once topped the scales at 237lbs in 1992 - finally reached her 160lb goal weight in 2023 after undergoing double-knee replacement surgery in 2021 The TV personality, 71 - who once topped the scales at 237lbs in 1992 - finally reached her 160lb goal weight in 2023 after undergoing double-knee replacement surgery in 2021 The Ozempic wedding! Celebrities including Oprah showed off their skinny waistlines at Lauren Sanchez and Jeff Bezos' wedding extravaganza in Venice on Thursday wearing a Valentino Garavani dress Oprah is pictured in August 2019 before her weight loss Kim Kardashian and bride-to-be Lauren Sanchez showcased their tiny waistlines at the pre-wedding party Suddenly slim Leonardo DiCaprio also revealed his trim new look (left, and right in 2019) The wedding ceremony itself is set to take place on Friday, June 27 - but festivities are already underway in preparation for the big day. Oprah looked more confident than ever at the pre-wedding party while sporting a purple and white-colored ensemble with small cutouts on the sides that showcased her shrinking midriff. The former talk show host has showed off her slimmer figure in recent months - such as when she made an appearance at the 2025 Tony Awards in NYC. Back in 2023, the star admitted to taking weight loss medication and at the time she told People, 'I now use it as I feel I need it, as a tool to manage not yo-yoing... 'The fact that there's a medically approved prescription for managing weight and staying healthier, in my lifetime, feels like relief, like redemption, like a gift, and not something to hide behind and once again be ridiculed for.' Winfrey added, 'I'm absolutely done with the shaming from other people and particularly myself' and explained she had recommended weight loss drugs to people before making the choice to also take the medication for herself. However, despite her weight loss journey being aided by medication, Oprah told the outlet that she also sticks to a fitness regime to also shed pounds, and maintain a lower weight. And earlier this year in January, the star expressed that taking weight-loss drugs, like Ozempic and Wegovy, helped her realize the truth about 'thin people.' Oprah - who has lost nearly 50 pounds with the aid of one of the newly popular weight-loss drugs - was seen arriving to Venice on Thursday She once again gave a glimpse at her smaller frame as she attended a party later on Thursday while sporting a purple and white-colored ensemble with small cutouts on the sides Kim Kardashian has also recently sparked surgery speculation as she continues to flashy her very tiny waistline. As she arrived to Venice on Thursday, the TV personality showcased her sculpted midriff in a Balenciaga outfit. The mom-of-four donned a strapless, black bandeau top as well as a maxi skirt and snakeskin boots. Her slim waist was further put on display as she later also stopped by the star-studded bash in a snakeskin Versace dress that clung to her curves and had small cutouts on the front. Bedazzled embellishments were added on the plunging neckline as well as the straps that wrapped around her shoulders. The star's long dark locks were parted in the middle and effortlessly flowed down past her shoulders in light waves. Kim has briefly opened up about her size in the past, such as in 2018 when Elle Magazine reported that she had a 24 inch waist and hips that measured 39 inches. The media personality also notably dropped 21 pounds in order to fit into Marilyn Monroe's iconic dress for the Met Gala back in 2022. The bride-to-be Lauren Sanchez also flaunted her slim waist while heading to Thursday's party in Venice. She wore a strapless gold dress with a fitted, corset bodice as well as intricate embroidery on the skirt and top portion. The journalist slipped into a pair of closed-toed, gold pumps and styled her locks into a chic ponytail. Bezos was seen helping Lauren into a boat as they headed to their next destination and the pair later sent waves to onlookers nearby. Speculation has previously arisen that Sanchez has undergone procedures such as a facelift and injectable fillers. Back in April, she uploaded an Instagram clip ahead of her Blue Origin space trip - and plastic surgeons told that they believe she had additional fillers in her cheeks and lips as well as fresh Botox around her eyes at the time. Khloe Kardashian was also seen joining her mom Kris Jenner and most of her siblings during the wedding extravaganza this week. The Good American founder put on a stylish display wearing a fitted dress with small cutouts on the material and a lowcut neckline. Earlier in the day, the beauty showed off her toned figure wearing an animal-print jumpsuit as she arrived to Venice. Last week on her Khloe In Wonder Land podcast, she addressed the 'gross' reaction that she got over her weight loss. 'The bigger I was, I was way more confident. I think because, like, what are going to say about me? I know all the things you're going to say. I would have my days that I would feel low and all of that.' She added, 'When I started my fitness journey and, like, becoming in shape, I felt such a need that I had to keep this up, like even if it wasn't for me. I felt like, "Well, I can't get fat again, because everyone is expecting that to happen." 'It was also a different type of attention I was now receiving. And then once I got a little older, I was like, "Wait, this is gross." I hated that that's why I was getting more attention because I looked a certain way.' Khloe later reflected, 'I've learned, no matter what, I'm never going to make people happy because I was once bigger, I was thinner, and I had the same amount of people, but from different ends.' Gayle King - who has also recently showed off her slimmed-down look - was also spotted during the festivities on Thursday. The TV personality was seen arriving to the Venice Marco Polo airport wearing a long-sleeved white top as well as pastel green cargo pants. Gayle King - who has also recently showed off her slimmed-down look - was also spotted during the festivities on Thursday King later dressed to impress alongside Oprah wearing a yellow and white-colored dress for the bash. In recent months, fans have begun to speculate that Gayle may have also used Ozempic to help aid in weight loss. Slimmed-down Leonardo DiCaprio was also seen making an appearance on Thursday with his supermodel girlfriend Vittoria Ceretti. The Titanic actor wore a classic black suit as well as a white dress shirt and a black cap that was placed on top of his head. Fans had previously pointed out the Oscar winner's fuller figure but he appears to have gone back to his leaner frame in the latest outing this week. Bezos and Sanchez's $20 million ceremony will take place on Friday - although it was revealed on Thursday that the couple are already legally married. A source told 'They have been married for at least a month, more than a month. The marriage is fully legal and took place in America under American law.' They added, 'When they were planning the wedding, they were clear about the fact that they were already secretly married. Slimmed-down Leonardo DiCaprio was also seen making an appearance on Thursday with his supermodel girlfriend Vittoria Ceretti Bezos and Sanchez's $20 million ceremony will take place on Friday - although it was revealed on Thursday that the couple are already legally married; seen in May in France 'There is no application for a wedding license from the couple because it was not required. 'Whatever happens at the wedding on Friday, it will not be a wedding. Under Italian law, it will not be a wedding celebration, any vows said or rings exchanged will have no legal meaning,' the insider continued. It was also added that the billionaire confirmed both he and Lauren are legally married and that they have signed a prenuptial agreement as well. The A-list guests that are attending the wedding - including the Kardashian/Jenner clan - are staying at five star hotels in Venice such as the Aman, The Gritti Palace and the Cipriani.
Yahoo
5 hours ago
- Business
- Yahoo
Why This Weight Loss Drug Company's Stock Surged Today
Investors are optimistic about the initiation of a phase 3 trial for a weight loss drug from Viking Therapeutics. The real value in the biopharmaceutical company may lie in the oral formulation of the drug. 10 stocks we like better than Viking Therapeutics › Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move likely stems from the market digesting the previous day's news that Viking had initiated a phase 3 trial of its most promising program in its pipeline, namely VK2375, a treatment for metabolic disorders, including obesity. There are probably two key reasons why the market likes the initiation of a phase 3 trial: VK2375 is a dual GLP-1/GIP receptor agonist similar to Eli Lilly's blockbuster weight loss drug Zepbound. Viking is developing VK2375 in both subcutaneous (under the skin) and oral formulations. The subcutaneous phase 3 trial is currently underway, while the phase 2 oral dosing trial results are expected to be released later this year. For reference, Novo Nordisk also offers a highly successful weight loss drug, Wegovy, a GLP-1 receptor agonist. While Viking Therapeutics, with a $3.2 billion market capitalization, will face challenges in competing with Eli Lilly's Zepbound unless it can demonstrate superior efficacy in the phase 3 trial, the real value in the business may lie in the oral formulation. There are obvious convenience and accessibility advantages to an oral formulation over a subcutaneous one, and a successful phase 2 trial may encourage a much larger pharmaceutical company to consider acquiring the company to take it through phase 3. As such, look out for the phase 2 results later in the year. In addition, note that Novo Nordisk has submitted to the FDA for approval of an oral formulation of Wegovy , and Eli Lilly recently reported positive results in a phase 3 trial for an oral GLP-1 agonist, orforglipron. All this means that the field is getting crowded. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,731!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $945,846!* Now, it's worth noting Stock Advisor's total average return is 818% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. Why This Weight Loss Drug Company's Stock Surged Today was originally published by The Motley Fool Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Health Line
9 hours ago
- Health
- Health Line
Will Medicare Pay for the Pill Form of Semaglutide?
Semaglutide is a prescription medication. Injectable forms of the drug are available under the brand names Ozempic and Wegovy. The pill form of semaglutide is available as the brand-name drug Rybelsus. Medicare drug plans usually cover Rybelsus when doctors prescribe it for type 2 diabetes. Medicare coverage of the pill form of semaglutide The Food and Drug Administration (FDA) has approved Rybelsus, the pill form of semaglutide, to lower blood sugar levels when taken along with exercise and diet in people with type 2 diabetes. If you have a Part D prescription drug plan or a Medicare Advantage (Part C) plan with drug benefits, your plan may cover Rybelsus if your doctor prescribes it for this FDA-approved use. Every Medicare drug plan has a list of covered drugs called a formulary. Not all Medicare plans may cover Rybelsus. If you're unsure whether your plan may cover Rybelsus, check its formulary or contact a plan representative. Medicare coverage of semaglutide for weight loss Some doctors prescribe the pill form of semaglutide off-label to assist with weight loss. 'Off-label' use describes taking a drug for a purpose the FDA hasn't approved. Medicare doesn't cover drugs when people take them off-label. For this reason, it doesn't cover the pill form of semaglutide for weight loss.
BreakingNews.ie
9 hours ago
- Health
- BreakingNews.ie
Pancreatitis cases linked to weight loss jabs
Ireland's medicines watchdog has confirmed a number of reports of pancreatitis linked to weight loss jabs. GLP-1 drugs like Ozempic and Mounjaro are under review in the UK after a spike in adverse reactions. Advertisement The Health Products Regulatory Authority (HPRA) said the number of Irish cases is very low, but people should consult their doctor if they are concerned. HSE national clinical lead for obesity, Professor Donal O'Shea, said it is important people use these drugs under medical supervision. Prof O'Shea said: "The main side effects are gastrointestinal and that's around nausea, vomiting, constipation, but they can cause unsteadiness and dizziness. "And I've certainly seen people coming into hospital having had falls on these treatements, and again the advice is not to take these unless they are prescribed by a healthcare professional."
Daily Mail
9 hours ago
- Health
- Daily Mail
ANNE ASHWORTH asks if it's worth investing in weight-loss drugs
There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and tycoons – including Elon Musk, Boris Johnson, Sharon Osbourne and Oprah Winfrey – who have used Ozempic or Mounjaro. In Britain, such has been the increase in uptake of these GLP-1 drugs that supermarket sales are shrinking. Sometimes this kind of coverage can have a wider message for investors. Public figures' reliance on 'fat jabs' underlines the forecast that the global market for these products could grow from the current $30billion (£22.4billion) to more than $150billion by the end of the decade, as millions seek a route out of obesity. So could you add weight to your portfolio by taking a slice of Eli Lilly, the US maker of Mounjaro, which is now being prescribed by GPs? Or should you opt for Novo Nordisk, the Danish giant that produced blockbuster brands Ozempic and Wegovy? An opportunity could lie in the weakness of shares of these ground-breaking businesses. Over the past year, Eli Lilly is down 13 per cent and Novo Nordisk has tumbled by 53 per cent. Will James, manager of the Guinness European Equity Income Fund, says: 'Novo Nordisk has been in the eye of the storm of late and its fall from grace has been impressive.' The two companies are battling not only against each other, but also with rival start-ups against a tense political background in the US. This is the largest market for weight-loss drugs, but US health secretary Robert F Kennedy Jr is not a fan. He wants to drive down the cost of all drugs. But he also believes that overeating is not the prime cause of obesity. He said: 'American kids did not suddenly get gluttonous and lazy – something is poisoning them.' Kennedy points the finger at the food companies. Although his assertions may not have any basis in fact, firms in this industry are already concerned about the impact of fat jabs on eating habits. The consultancy company Kantar says that lower supermarket sales have coincided with increased uptake of GLP-1 treatments. A year ago, 2.3 per cent of UK households had one member using GLP-1. It now stands at 4.1 per cent. NOVO NORDISK A bet on Novo Nordisk is a gamble on a corporate comeback. Almost exactly a year ago, the shares – priced in DKK, or Danish krone – were at their peak of Kr.1,208, against Kr.441. The pharmaceutical giant, set up a century ago, was greater in size than the Danish economy, and had become what James describes as 'the flag bearer for Europe's sometimes-doubted ability to innovate'. Today, Novo Nordisk looks more vulnerable than all-conquering. So much so that the activist hedge fund Parvus Asset Management has been amassing a stake, presumably to force a shake-up. Also pressing for change is the largest shareholder, the Novo Foundation. This follows the unseating in May of Novo Nordisk's chief executive Lars Fruergaard Jorgensen, only the fifth person to have held this role in the company's history. His departure was spurred by Eli Lilly's rapid seizure of market share in the US, where Mounjaro is the most-prescribed drug. Novo Nordisk remains the global leader, however. The problems began last year when Novo Nordisk could not satisfy demand for its drugs, leading to a damaging surge in 'compounding'. Under this arrangement, pharmacies can mix cheap copycat versions of drugs: the customers of US online telehealth companies, such as Hims & Hers Health, proved to be more than keen on 'Ozempic dupes'. The situation was exacerbated by the poor performance in a trial of new weight-loss treatment CagriSema. But Novo Nordisk is trying to shift the perception of the drug with its additional cardiovascular benefits. Meanwhile, Amycretin, another new-generation drug, appears to be delivering results superior to Mounjaro. Amycretin is administered as a once-weekly injection and a daily pill. A few months ago there may have been speculation that Novo Nordisk could turn out to be the pharmaceutical equivalent of MySpace – the pre-eminent social media site that sank into obscurity when Facebook emerged. However, in recent weeks the pessimism surrounding the company has lessened. James says: 'This is a high-quality, high-return business with an impressive track record of success and improving people's lives.' The shares are on a p/e ratio (a guide to value) of 17 times earnings. At the height of Novo Nordisk's hype, this was 40 times. This upbeat assessment is shared by brokers. In the past few days, Barclays, Deutsche, JP Morgan and UBS have reiterated their 'buy' recommendations. ELI LILLY Eli Lilly might be best known for Mounjaro, but its pipeline includes cancer and diabetes drugs and products for Alzheimer's and Crohn's disease. Established in 1876, it has also just snapped up the gene-editing start-up Verve Therapeutics for $1.3billion as a way to expand beyond weight-loss drugs, while making the most of its expertise in this area. If approval is forthcoming, Eli Lilly plans to launch Orforglipron, a once-a-day pill, next year. This represents considerable progress for a business once most-closely associated with the anxiety medication Prozac, which is no longer manufactured. The scope of Eli Lilly's range evidently inspires confidence, since 17 of the 29 analysts that follow the company rate the shares a buy with an average target price of $951, against the current $780. Putting some money into Eli Lilly and Novo Nordisk makes sense if you are diversifying your portfolio this summer and want to invest in innovation. However, both Novo Nordisk and Eli Lilly face huge competition, with about 150 rival products in development. Not all are guaranteed immediate success. This week, for example, shares in the US pharmaceutical company Amgen slipped by 6 per cent on news that its MariTide weight-loss injectable caused vomiting. Novo Nordisk is one of the top ten holdings at the giant Fundsmith fund. However, its portfolio no longer includes the drinks group Diageo, in a wider shift triggered by the impact of weight-loss drugs. Companies such as Associated British Foods, McDonald's, Mondelez, Nestle, PepsiCo, Tate & Lyle and Unilever are aware of the need to adapt as consumers move away from alcohol, confectionery, fizzy drinks and snacks. They must shape up for the fat-jab age – or face investors' ire.
